Musician P!nk to be newest face of CoverGirl
HUNT VALLEY, Md. — Procter & Gamble’s CoverGirl has partnered with musician P!nk, who recently wrapped her first print advertising campaign with the brand, which will debut in the fall.
“P!nk is a powerful and provocative role model, who has always been an advocate of individualism and making no apologies for who you are,” stated Esi Eggleston Bracey, VP and general manager for CoverGirl Cosmetics. “That combination of irreverence and integrity is exactly what the CoverGirl brand loves about her and identifies with. We have admired P!nk’s art and her attitude for years. We love the energy and confidence that she radiates, and the fact that inside and out she’s as cool as she looks. She’s an awesome addition to our CoverGirl family.”
Throughout her career, P!nk has built a reputation for being a fearless, fun innovator; sSo it’s fitting that later this fall, as the first chapter of her CoverGirl story, the singer will be the face of a bold new mascara innovation from the brand. In the months ahead, P!nk will debut many more new beauty looks on her lashes, lips and everything in between.
Since its introduction in 1961, the CoverGirl brand has been a pioneer in providing women with the makeup tools to rock their everyday cover moments. The long list of famous CoverGirls has included Christie Brinkley, Cheryl Tiegs, Rachel Hunter, Tyra Banks, Niki Taylor and Molly Sims. The current roster of CoverGirls includes such icons as Sofia Vergara, Queen Latifah, Drew Barrymore, Ellen DeGeneres, Taylor Swift and Canadian Olympian Mary Spencer.
Teva, Active Biotech plan third MS drug trial
JERUSALEM — Drug makers Teva Pharmaceutical Industries and Active Biotech will start a third late-stage clinical trial of an experimental drug for treating multiple sclerosis, the companies said Wednesday.
Israel-based Teva and Sweden-based Active Biotech said they would start a phase-3 trial of laquinimod for relapsing-remitting multiple sclerosis, also known as RRMS, following an agreement with the Food and Drug Administration.
"The results achieved in the previous phase-3 trials of laquinimod support the clinical utility of this compound as a unique treatment option for multiple sclerosis," Teva president of global research and development and chief scientific officer Michael Hayden said. "We are encouraged by the FDA’s agreement on the trial design and planned analysis and look forward to further developing laquinimod as a potential treatment option for RRMS patients."
The trial, dubbed "CONCERTO," will evaluate the once-daily oral drug in the 0.6-mg and 1.2-mg doses, enrolling about 1,800 patients for up to 24 months.
Yoplait Greek 100 makes market debut
MINNEAPOLIS — Yoplait has introduced a 100-calorie strained Greek yogurt.
Yoplait Greek 100 is fat free and contains twice the amount of protein when compared with regular yogurt, Yoplait said. Packed in 5.3-oz. cups, the yogurt is available in such flavors as strawberry, black cherry, mixed berry, vanilla, peach and key lime.
"Greek yogurt has everything people are looking for in a snack, but sometimes, the calories can add up for those watching their intake," Yoplait Greek 100 marketing manager Liza Dopp said. "We’ve heard from calorie conscious consumers that there is a need for Greek yogurts with less than 150 calories, and we’re thrilled that Yoplait Greek 100 can answer that call."
Yoplait Greek 100 will be available nationwide this month for a suggested retail price of $1.29 per single-serve cup.